Date Filed | Type | Description |
10/06/2023 |
F-6 POS
| Form F-6 POS - Post-effective amendments for immediately effective filing: |
10/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
08/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/10/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
08/10/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/24/2023 |
6-K
| Quarterly results |
06/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
06/01/2023 |
F-1/A
| Form F-1/A - Registration statement for certain foreign private issuers: [Amend] |
06/01/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/18/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/11/2023 |
F-1/A
| Form F-1/A - Registration statement for certain foreign private issuers: [Amend] |
05/11/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/10/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/05/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Addex Convenes Annual General Meeting 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday May 31, 2023, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva . Agenda" |
|
04/05/2023 |
SC 13D/A
| Dyer Timothy Mark reports a 11.1% stake in Addex Therapeutics Ltd |
04/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
04/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/31/2023 |
SC 13D/A
| Dyer Timothy Mark reports a 12.2% stake in Addex Therapeutics Ltd |
03/30/2023 |
6-K
| Quarterly results |
03/30/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 0.9% stake in Addex Therapeutics Ltd |
02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in Addex Therapeutics Ltd |
02/09/2023 |
6-K
| Quarterly results |
02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/19/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/08/2022 |
6-K
| Quarterly results |
11/28/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
11/23/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|